发明名称 |
IL-2 TRANSMEMBRANE CONSTRUCTS |
摘要 |
Compounds, genetic constructs, and cancer treatment methods 035 provided. Expression vectors were designed to express fusion genes including hIL-2 wit h 0 FcT- transmembrane anchor derived from 0 subunit of the FC epsilon recepto r. mRN 0nd the IL~2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL~2tm protein on the tumor A511 surface membrane w as confirmed by microscopy. RD995 ce11s transfected with IL-2tm or pCMV2b (empt y expression vector) were implanted subcutaneously into !3 /HEN mice. Tumors i n groups of mice implanted with 106 or 105 RD995 ce11s transfected with IL-2tm grew slower than controls. Without being limited to any one theory, it is believed that selective expression >f cytokines such as IL-2 on the surfa ce >f tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition 0nd killin g, potentially avoiding toxicity associated with known cytokine therapies.</SDO AB>
|
申请公布号 |
CA2518383(A1) |
申请公布日期 |
2004.09.23 |
申请号 |
CA20042518383 |
申请日期 |
2004.03.08 |
申请人 |
UNIVERSITY OF UTAH RESEARCH FOUNDATION |
发明人 |
MCGREGOR, JOHN;ADAMS, NATHAN BRADLEY;SAMLOWSKI, WOLFRAM |
分类号 |
A61K38/00;B65D51/28;C07K14/55;C07K14/735;(IPC1-7):C12N15/62;C07K19/00;A61P35/00;C12P21/02;C12N15/12;A61K38/17;A61K38/20;C12N15/26 |
主分类号 |
A61K38/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|